| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/18/2010 | US20100041645 Rho kinase inhibitors |
| 02/18/2010 | US20100041639 Cyclic malonamides as inhibitors of a beta protein production |
| 02/18/2010 | US20100041624 Buprenorphine formulations for intranasal delivery |
| 02/18/2010 | US20100041620 Methods for improving frontal brain bioenergetic metabolism |
| 02/18/2010 | US20100041619 Lasonolide compounds as reagents for inducing premature chromosome condensation and methods for treating disorders |
| 02/18/2010 | US20100041601 Use of VEGF and homologues to treat neuron disorders |
| 02/18/2010 | US20100041072 Process for identifying a ligand that binds to the nep binding site for the smr1 pentapeptide |
| 02/18/2010 | US20100040679 Compositions for Reducing Nicotine Withdrawal Symptoms and/or Tobacco Usage |
| 02/18/2010 | US20100040660 Development of a tissue - engineered scaffold for nerve regeneration using a biocompatible and injectable hydrogel |
| 02/18/2010 | US20100040626 Methods for detecting and treating attention-deficit/hyperactivity disorder |
| 02/18/2010 | US20100040612 Methods and compositions for reducing amyloid beta levels |
| 02/18/2010 | US20100040604 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 02/18/2010 | US20100040586 Treatment of Injuries to the Central Nervous System |
| 02/18/2010 | US20100040575 Use of inhibitors of glutaminyl cyclase and glutamate cyclase for treatment and prevention of neurodegenerative diseases |
| 02/18/2010 | US20100040556 Carrier nanoparticles and related compositions, methods and systems |
| 02/18/2010 | CA2734766A1 Compositions and methods for treatment during non-acute periods following cns neurological injury |
| 02/18/2010 | CA2734082A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | CA2734077A1 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-ib]-pyridazine derivatives, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | CA2733922A1 A crystalline form of 4-(5-{(1r)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine |
| 02/18/2010 | CA2733920A1 A new crystalline form of 4-(5-{(1r)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine |
| 02/18/2010 | CA2733775A1 Agent for promoting neuronal differentiation and method therefor |
| 02/18/2010 | CA2733646A1 Acetyl pyrrolidinyl indole derivative |
| 02/18/2010 | CA2733642A1 Anti-il-12/il-23 antibodies |
| 02/18/2010 | CA2733397A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | CA2732784A1 Compositions comprising terpene compounds for treating negative sensory phenomena |
| 02/18/2010 | CA2728451A1 Salicylamide derivatives as nicotinic alpha 7 modulators |
| 02/17/2010 | EP2154139A1 Bicyclic heterocyclic compound |
| 02/17/2010 | EP2154138A1 Novel compounds for treatment of psychotic disorders, preparation methods and uses thereof |
| 02/17/2010 | EP2154131A1 G protein-coupled receptor inhibitor and pharmaceutical product |
| 02/17/2010 | EP2153847A1 Gene sensitive to bone/joint disease and use thereof |
| 02/17/2010 | EP2153844A1 Human hyaluronidases for axonal regrowth |
| 02/17/2010 | EP2153832A2 Heterocyclic aspartyl protease inhibitors |
| 02/17/2010 | EP2153829A1 Methods of preventing, treating and diagnosing disorders of protein aggregation |
| 02/17/2010 | EP2153819A2 Compositions containing therapeutically active components having enhanced solubility |
| 02/17/2010 | EP2152748A1 Anti-notch1 nrr antibodies and methods using same |
| 02/17/2010 | EP2152713A1 Pyrazolopyrrolidines as inhibitors of gamma secretase |
| 02/17/2010 | EP2152695A2 Gamma secretase modulators |
| 02/17/2010 | EP2152690A1 Pyridyl piperidine orexin receptor antagonists |
| 02/17/2010 | EP2152679A1 Benzisoxazole derivatives as potassium channel modulators for the treatment of e.g. respiratory diseases, epilepsy and convulsions |
| 02/17/2010 | EP2152672A1 Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors |
| 02/17/2010 | EP2152368A1 Substituted phosphonates and their use in decreasing amyloid aggregates |
| 02/17/2010 | EP2152315A2 Sustained delivery formulations of risperidone compounds |
| 02/17/2010 | EP2152313A1 Oral nicotine formulation buffered with amino acid |
| 02/17/2010 | EP2152309A1 Methods and device to neutralize soluble toxic agents in the brain |
| 02/17/2010 | EP2152292A1 Angiogenesis inhibitor comprising meteorin as an active ingredient |
| 02/17/2010 | EP2152272A2 Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| 02/17/2010 | EP2152256A2 Telomerase activating compounds and methods of use thereof |
| 02/17/2010 | EP2152255A1 Ophthalmic formulations of amyloid- contrast agents and methods of use thereof |
| 02/17/2010 | EP2152247A1 Anti-insomnia compositions and methods |
| 02/17/2010 | EP2152238A2 Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| 02/17/2010 | EP2152227A1 A liquid formulation for administering nicotine |
| 02/17/2010 | EP2091942B1 Substituted pyrazinone derivatives for use as a medicine |
| 02/17/2010 | EP2038285B1 Adenosine a2a receptor antagonists |
| 02/17/2010 | EP1979321B9 Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them |
| 02/17/2010 | EP1828200B1 Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer's disease. |
| 02/17/2010 | EP1773827B1 Benzothiazole derivatives |
| 02/17/2010 | EP1758888B1 Butyrylcholinesterase selective inhibitors |
| 02/17/2010 | EP1511737B1 Aryloximes |
| 02/17/2010 | EP1347950B1 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of gamma-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses |
| 02/17/2010 | CN101648941A 4-tetrazolyl-4phenylpiperidine derivatives for treating pain |
| 02/16/2010 | US7662995 1-(2-Fluoro-4'-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid, for example; treatment and/or prevention of Alzheimer's disease; inhibiting the release of A beta 42 peptide thereby being able to modulate gamma-secretase activity without affecting other important metabolic processes |
| 02/16/2010 | US7662977 Such as 2-cationic amino-4-oxo-chromene derivatives; water solubility, pharmacokinetics; reduced side effects; anticancer agents |
| 02/16/2010 | US7662971 enzyme inhibitor for treating sleep disorders |
| 02/16/2010 | US7662948 Antisense oligonucleotides against VR1 |
| 02/16/2010 | US7662933 Pegylated granulocyte colony stimulating factor (G-CSF) to treat a hematopoietic disorder related to reduced neutrophil count, such as infectious disease, sepsis, or a result of radiotherapy or chemotherapy |
| 02/16/2010 | US7662854 HIF hydroxylase inhibitors |
| 02/16/2010 | US7662849 N-cyanomethyl-2R-[(benzenesulfonyliminomethyl)amino]-3-(2-difluoromethoxyphenylmethanesulfonyl)-propionamide; treating autoimmune disorders |
| 02/16/2010 | US7662845 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 |
| 02/16/2010 | US7662843 Isoxazoline compounds having MIF antagonist activity |
| 02/16/2010 | US7662828 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds |
| 02/16/2010 | US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma |
| 02/16/2010 | US7662817 Psychological disorders; central nervous system disorders; antidepressants; anxiolytic agents; stress reliever; irritable bowel syndrome |
| 02/16/2010 | US7662812 disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances |
| 02/16/2010 | US7662805 Mixture of antidepressant such as serotonine receptor antagonist, with acetylsalicylic acid |
| 02/16/2010 | US7662633 Method of screening for inhibitors of osteopontin |
| 02/16/2010 | US7662620 Stem cell-derived neuron survival factor polypeptides (SDNSF) for use in prevention and treatment of cell proliferative, neurodegenerative and cardiovascular disorders |
| 02/16/2010 | US7662392 Stromal-Derived Factor-1 (SDF), G-CSF (granulocyte-colony stimulating factor), stimulating vasculogenesis; improves cardiac function |
| 02/16/2010 | US7662371 Composition for lowering the concentration of intestinal pathogenic peptides |
| 02/16/2010 | US7662365 Polymer conjugates of opioid antagonists |
| 02/16/2010 | CA2478183C Substituted amides |
| 02/16/2010 | CA2450922C Piperidines for use as orexin receptor antagonists |
| 02/16/2010 | CA2442882C Sulphones which modulate the action of gamma-secretase |
| 02/16/2010 | CA2440037C Benzimidazole derivatives for modulating the rage receptor |
| 02/16/2010 | CA2422267C Drying method for selectively removing volatile components from wet coatings |
| 02/16/2010 | CA2410939C Materials and methods for the treatment of gastroesophageal reflux disease |
| 02/16/2010 | CA2402436C Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 02/16/2010 | CA2346082C Tricyclic .delta.3-piperidines as pharmaceuticals |
| 02/11/2010 | WO2010017541A2 Compositions and methods for treatment of neurodegenerative disease |
| 02/11/2010 | WO2010017468A1 Treatment of autoimmune and inflammatory disease |
| 02/11/2010 | WO2010017466A2 Phenobarbital salts; methods of making; and methods of use thereof |
| 02/11/2010 | WO2010017418A1 Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| 02/11/2010 | WO2010017368A2 Methods and compositions for treating anxiety |
| 02/11/2010 | WO2010017343A2 Flupirtine hydrochloride maleic acid cocrystal |
| 02/11/2010 | WO2010017272A2 Method of treating neurological diseases |
| 02/11/2010 | WO2010017224A2 Methods of treating cognitive impairment |
| 02/11/2010 | WO2010017216A2 Mesenchymal stromal cell populations and methods of isolating and using same |
| 02/11/2010 | WO2010017120A1 Cyclopropylchromene derivatives as modulators of the alpha-2c receptor |
| 02/11/2010 | WO2010017093A2 Dopamine receptor ligands with enhanced duration of action |
| 02/11/2010 | WO2010017079A1 Oxazole derivatives useful as inhibitors of faah |
| 02/11/2010 | WO2010016844A1 Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis |